“…Evidence shows that 6 months after a gastric bypass, there is a significant reduction in the expression of mRNA linked to APP, presenilin-2, ADAM-9, GSK-3B, PICALM, SORL-1 and clusterin besides an important clinical improvement of cognitive capabilities of patients who have undergone bariatric surgery [42]. Patients that undergo gastric bypass have a reduced risk of coronary disease, peripheral angiopathy, stroke, diabetic nephropathy, peripheral neuropathy [43,44] as well as diabetic retinopathy [45]. In the case of nephropathy [46], an improvement on the tissular damage and overall function markers has been observed, which has allowed for replacement therapy to be interrupted or delayed temporarily [47].…”